Have you ever thought about the well-being of your employees? At beLean.net this is a crucial aspect and it is now more than ever important to invest in the well-being and health of our team. This is why we have chosen to work with Conscious Motions, a young start-up whose focus is to help companies implement[…]
BELEAN.NET: We are part-time CFO for start-ups and scale-ups in biotech and digital. We support companies in strategy, fundraising, M&A, Due Diligence, business modelling, financial controlling, implementation of internal processes and ERP. MISSION: Supported by the partners and seniors of beLean.net, you participate directly in the various CFO missions. YOU: You are passionated about start-ups and technology and you[…]
OncoDNA, the genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, will customize its interpretation platform OncoKDM to make it compatible with SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform. The combined offering will enable the analysis and automatic translation of complex genomic data obtained via SOPHiA DDM™ into actionable recommendations, empowering[…]
The current health crisis has highlighted the resilience that Belgian companies have shown to accelerate research and allow the development, in record time, of multiple therapeutic solutions to counter the Covid-19 pandemic. This social responsibility is the proof of the value that an innovative biopharmaceutical industry could bring with its expertise in dealing with an epidemic.[…]
A first-round funding of 3 millions euros has been raised by Vésale Bioscience, the spin-out of the Vésale Pharma group which focuses on phagotherapy. In order to increase its financial resources and reach the stock market, the group has hired beLean.net Partner Guillaume de Viron as Head of Finance for the phage therapy division. Co-founder of Univercells, former CFO of MaSTHerCell,[…]
Vésale Bioscience has hired Guillaume de Viron, Partner at beLean.net, as Chief Financial Officer in order to accelerate its IPO. As CFO, Guillaume de Viron will contribute to Vésale Bioscience, which is currently preparing its fundraising (10+ million €) with the aim of accelerating the production and marketing of phages. Phage therapy is the use of phages,[…]